Bifidobacterium bacteremia: Clinical characteristics and a genomic approach to assess pathogenicity

Journal of Clinical Microbiology

Volumn 55, Issue 7, 2017, Pages 2234-2248

  Esaiassen, Eirin ^a,b   Hjerde, Erik ^b   Cavanagh, Jorunn Pauline ^a,b   Simonsen, Gunnar Skov ^a,b   Klingenberg, Claus ^a,b  

^a UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

Author keywords

Antibiotic resistance; Bifidobacteria; Blood culture; Bloodstream infections; DNA sequencing; Mass spectrometry; Pangenome; Probiotics; Susceptibility testing; Virulence factors

Indexed keywords

AMPICILLIN; BETA LACTAM ANTIBIOTIC; CEFOTAXIME; CEFTRIAXONE; CIPROFLOXACIN; CLINDAMYCIN; GENTAMICIN; MEROPENEM; METRONIDAZOLE; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; VANCOMYCIN; ANTIINFECTIVE AGENT; VIRULENCE FACTOR;

ADULT; AGE; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; BACTERIAL GENE; BACTERIAL GENOME; BACTERIAL VIRULENCE; BACTERIUM ISOLATE; BIFIDOBACTERIUM; BIFIDOBACTERIUM ANIMALIS; BIFIDOBACTERIUM BREVE; BIFIDOBACTERIUM LONGUM; BLOOD CULTURE; CAUSE OF DEATH; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GASTROINTESTINAL DISEASE; GENOMICS; GENOTYPE; HUMAN; IMMUNOCOMPROMISED PATIENT; INFANT; MALE; MIDDLE AGED; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHENOTYPE; PHYLOGENY; PRIORITY JOURNAL; SEPSIS; SPECIES IDENTIFICATION; STRAIN DIFFERENCE; VERY ELDERLY; WHOLE GENOME SEQUENCING; CLASSIFICATION; GENETICS; GRAM POSITIVE INFECTION; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; NEWBORN; NORWAY; PATHOGENICITY; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTEREMIA; BIFIDOBACTERIUM; FEMALE; GENOMICS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; INFANT; INFANT, NEWBORN; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; NORWAY; RETROSPECTIVE STUDIES; VIRULENCE FACTORS; WHOLE GENOME SEQUENCING;

EID: 85021294690     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.00150-17     Document Type: Article

References (51)

1. Saavedra JM. 2007. Use of probiotics in pediatrics: rationale, mechanisms of action, and practical aspects. Nutr Clin Pract 22:351-365. https://doi.org/10.1177/0115426507022003351.
2. Lewis ZT, Totten SM, Smilowitz JT, Popovic M, Parker E, Lemay DG, Van Tassell ML, Miller MJ, Jin YS, German JB, Lebrilla CB, Mills DA. 2015. Maternal fucosyltransferase 2 status affects the gut bifidobacterial communities of breastfed infants. Microbiome 3:13. https://doi.org/10.1186/s40168-015-0071-z.
3. Milani C, Turroni F, Duranti S, Lugli GA, Mancabelli L, Ferrario C, van Sinderen D, Ventura M. 2015. Genomics of the genus Bifidobacterium reveals species-specific adaptation to the glycan-rich gut environment. Appl Environ Microbiol 82:980-991. https://doi.org/10.1128/AEM.03500-15.
4. Bottacini F, Ventura M, van Sinderen D, O'Connell Motherway M. 2014. Diversity, ecology and intestinal function of bifidobacteria. Microb Cell Fact 13(Suppl 1):S4. https://doi.org/10.1186/1475-2859-13-S1-S4.
5. Arboleya S, Watkins C, Stanton C, Ross RP. 2016. Gut bifidobacteria populations in human health and aging. Front Microbiol 7:1204. https://doi.org/10.3389/fmicb.2016.01204.
6. Collado MC, Gueimonde M, Hernandez M, Sanz Y, Salminen S. 2005. Adhesion of selected Bifidobacterium strains to human intestinal mucus and the role of adhesion in enteropathogen exclusion. J Food Prot 68:2672-2678. https://doi.org/10.4315/0362-028X-68.12.2672.
7. Serafini F, Strati F, Ruas-Madiedo P, Turroni F, Foroni E, Duranti S, Milano F, Perotti A, Viappiani A, Guglielmetti S, Buschini A, Margolles A, van Sinderen D, Ventura M. 2013. Evaluation of adhesion properties and antibacterial activities of the infant gut commensal Bifidobacterium bifidum PRL2010. Anaerobe 21:9-17. https://doi.org/10.1016/j.anaerobe.2013.03.003.
8. Round JL, Mazmanian SK. 2009. The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol 9:313-323. https://doi.org/10.1038/nri2515.
9. Nicola S, Amoruso A, Deidda F, Pane M, Allesina S, Mogna L, Del Piano M, Mogna G. 2016. Searching for the perfect homeostasis: five strains of Bifidobacterium longum from centenarians have a similar behavior in the production of cytokines. J Clin Gastroenterol 50(Suppl 2):S126-S130.
10. Pokusaeva K, Fitzgerald GF, van Sinderen D. 2011. Carbohydrate metabolism in Bifidobacteria. Genes Nutr 6:285-306. https://doi.org/10.1007/s12263-010-0206-6.
11. El-Soud NH, Said RN, Mosallam DS, Barakat NA, Sabry MA. 2015. Bifidobacterium lactis in treatment of children with acute diarrhea. A randomized double blind controlled trial. Open Access Maced J Med Sci 3:403-407. https://doi.org/10.3889/oamjms.2015.088.
12. Singhi SC, Kumar S. 2016. Probiotics in critically ill children. F1000Res 5:407. https://doi.org/10.12688/f1000research.7630.1.
13. Yi SH, Jernigan JA, McDonald LC. 2016. Prevalence of probiotic use among inpatients: A descriptive study of 145 U.S. hospitals. Am J Infect Control 44:548-553. https://doi.org/10.1016/j.ajic.2015.12.001.
14. Brook I. 1996. Isolation of non-sporing anaerobic rods from infections in children. J Med Microbiol 45:21-26. https://doi.org/10.1099/00222615-45-1-21.
15. Cohen SA, Woodfield MC, Boyle N, Stednick Z, Boeckh M, Pergam SA. 2016. Incidence and outcomes of bloodstream infections among hematopoietic cell transplant recipients from species commonly reported to be in over-The-counter probiotic formulations. Transpl Infect Dis 18: 699-705. https://doi.org/10.1111/tid.12587.
16. Weber E, Reynaud Q, Suy F, Gagneux-Brunon A, Carricajo A, Guillot A, Botelho-Nevers E. 2015. Bifidobacterium species bacteremia: risk factors in adults and infants. Clin Infect Dis 61:482-484. https://doi.org/10.1093/cid/civ347.
17. Norwegian Organization for Surveillance of Antimicrobial Resistance. 2016. Usage of antimicrobial agents and occurrence of antimicrobial resistance in Norway. Norwegian Organization for Surveillance of Antimicrobial Resistance, Tromsø/Oslo, Norway.
18. Esaiassen E, Cavanagh P, Hjerde E, Simonsen GS, Stoen R, Klingenberg C. 2016. Bifidobacterium longum subspecies infantis bacteremia in 3 extremely preterm infants receiving probiotics. Emerg Infect Dis 22: 1664-1666. https://doi.org/10.3201/eid2209.160033.
19. Yu M, Zuo J, Gu H, Guo M, Yin Y. 2015. Domain function dissection and catalytic properties of Listeria monocytogenes p60 protein with bacteriolytic activity. Appl Microbiol Biotechnol 99:10527-10537. https://doi.org/10.1007/s00253-015-6967-5.
20. Marshall BJ, Barrett LJ, Prakash C, McCallum RW, Guerrant RL. 1990. Urea protects Helicobacter (Campylobacter) pylori from the bactericidal effect of acid. Gastroenterology 99:697-702. https://doi.org/10.1016/0016-5085(90)90957-3.
21. Bourne KA, Beebe JL, Lue YA, Ellner PD. 1978. Bacteremia due to Bifidobacterium, Eubacterium or Lactobacillus; twenty-one cases and review of the literature. Yale J Biol Med 51:505-512.
22. Sanchez B, Delgado S, Blanco-Miguez A, Lourenco A, Gueimonde M, Margolles A. 10 October 2016. Probiotics, gut microbiota, and their influence on host health and disease. Mol Nutr Food Res. https://doi.org/10.1002/mnfr.201600240.
23. Penders J, Stobberingh EE, Savelkoul PH, Wolffs PF. 2013. The human microbiome as a reservoir of antimicrobial resistance. Front Microbiol 4:87. https://doi.org/10.3389/fmicb.2013.00087.
24. Gueimonde M, Sanchez B, de los Reyes-Gavilán CG, Margolles A. 2013. Antibiotic resistance in probiotic bacteria. Front Microbiol 4:202. https://doi.org/10.3389/fmicb.2013.00202.
25. Varankovich NV, Nickerson MT, Korber DR. 2015. Probiotic-based strategies for therapeutic and prophylactic use against multiple gastrointestinal diseases. Front Microbiol 6:685. https://doi.org/10.3389/fmicb.2015.00685.
26. Didari T, Solki S, Mozaffari S, Nikfar S, Abdollahi M. 2014. A systematic review of the safety of probiotics. Expert Opin Drug Saf 13:227-239. https://doi.org/10.1517/14740338.2014.872627.
27. Borriello SP, Hammes WP, Holzapfel W, Marteau P, Schrezenmeir J, Vaara M, Valtonen V. 2003. Safety of probiotics that contain lactobacilli or bifidobacteria. Clin Infect Dis 36:775-780. https://doi.org/10.1086/368080.
28. Moubareck C, Gavini F, Vaugien L, Butel MJ, Doucet-Populaire F. 2005. Antimicrobial susceptibility of bifidobacteria. J Antimicrob Chemother 55:38-44.
29. Delgado S, Florez AB, Mayo B. 2005. Antibiotic susceptibility of Lactobacillus and Bifidobacterium species from the human gastrointestinal tract. Curr Microbiol 50:202-207. https://doi.org/10.1007/s00284-004-4431-3.
30. Mättö J, van Hoek AHAM, Domig KJ, Saarela M, Floréz AB, Brockmann E, Amtmann E, Mayo B, Aarts HJM, Danielsen M. 2007. Susceptibility of human and probiotic Bifidobacterium spp. to selected antibiotics as determined by the Etest method. Int Dairy J 17:1123-1131. https://doi.org/10.1016/j.idairyj.2007.01.008.
31. Lim KS, Huh CS, Baek YJ. 1993. Antimicrobial susceptibility of bifidobacteria. J Dairy Sci 76:2168-2174. https://doi.org/10.3168/jds.S0022-0302(93)77553-0.
32. Masco L, Van Hoorde K, De Brandt E, Swings J, Huys G. 2006. Antimicrobial susceptibility of Bifidobacterium strains from humans, animals and probiotic products. J Antimicrob Chemother 58:85-94. https://doi.org/10.1093/jac/dkl197.
33. Ouoba LI, Lei V, Jensen LB. 2008. Resistance of potential probiotic lactic acid bacteria and bifidobacteria of African and European origin to antimicrobials: determination and transferability of the resistance genes to other bacteria. Int J Food Microbiol 121:217-224. https://doi.org/10.1016/j.ijfoodmicro.2007.11.018.
34. Florez AB, Ammor MS, Alvarez-Martin P, Margolles A, Mayo B. 2006. Molecular analysis of tet(W) gene-mediated tetracycline resistance in dominant intestinal Bifidobacterium species from healthy humans. Appl Environ Microbiol 72:7377-7379. https://doi.org/10.1128/AEM.00486-06.
35. Ammor MS, Florez AB, Alvarez-Martin P, Margolles A, Mayo B. 2008. Analysis of tetracycline resistance tet(W) genes and their flanking sequences in intestinal Bifidobacterium species. J Antimicrob Chemother 62:688-693. https://doi.org/10.1093/jac/dkn280.
36. Aires J, Doucet-Populaire F, Butel MJ. 2007. Tetracycline resistance mediated by tet(W), tet(M), and tet(O) genes of Bifidobacterium isolates from humans. Appl Environ Microbiol 73:2751-2754. https://doi.org/10.1128/AEM.02459-06.
37. Charteris WP, Kelly PM, Morelli L, Collins JK. 1998. Antibiotic susceptibility of potentially probiotic Bifidobacterium isolates from the human gastrointestinal tract. Lett Appl Microbiol 26:333-337. https://doi.org/10.1046/j.1472-765X.1998.00342.x.
38. Löfmark S, Edlund C, Nord CE. 2010. Metronidazole is still the drug of choice for treatment of anaerobic infections. Clin Infect Dis 50:S16-S23. https://doi.org/10.1086/647939.
39. Collado MC, Gonzalez A, Gonzalez R, Hernandez M, Ferrus MA, Sanz Y. 2005. Antimicrobial peptides are among the antagonistic metabolites produced by Bifidobacterium against Helicobacter pylori. Int J Antimicrob Agents 25:385-391. https://doi.org/10.1016/j.ijantimicag.2005.01.017.
40. Kitamoto S, Nagao-Kitamoto H, Kuffa P, Kamada N. 2016. Regulation of virulence: The rise and fall of gastrointestinal pathogens. J Gastroenterol 51:195-205. https://doi.org/10.1007/s00535-015-1141-5.
41. Westermann C, Gleinser M, Corr SC, Riedel CU. 2016. A critical evaluation of bifidobacterial adhesion to the host tissue. Front Microbiol 7:1220. https://doi.org/10.3389/fmicb.2016.01220.
42. Bruker Daltonics. 2012. MALDI Biotyper 3.1 user manual. Bruker Daltonics, Bremen, Germany.
43. Illumina. 2016. Nextera® DNA library prep reference guide. Illumina, San Diego, CA.
44. Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS, Lesin VM, Nikolenko SI, Pham S, Prjibelski AD, Pyshkin AV, Sirotkin AV, Vyahhi N, Tesler G, Alekseyev MA, Pevzner PA. 2012. SPAdes: A new genome assembly algorithm and its applications to single-cell sequencing. J Comput Biol 19:455-477. https://doi.org/10.1089/cmb.2012.0021.
45. Contreras-Moreira B, Vinuesa P. 2013. GET-HOMOLOGUES, a versatile software package for scalable and robust microbial pangenome analysis. Appl Environ Microbiol 79:7696-7701. https://doi.org/10.1128/AEM.02411-13.
46. Li L, Stoeckert CJ, Jr, Roos DS. 2003. OrthoMCL: identification of ortholog groups for eukaryotic genomes. Genome Res 13:2178-2189. https://doi.org/10.1101/gr.1224503.
47. Huerta-Cepas J, Szklarczyk D, Forslund K, Cook H, Heller D, Walter MC, Rattei T, Mende DR, Sunagawa S, Kuhn M, Jensen LJ, von Mering C, Bork P. 2016. eggNOG 4.5: A hierarchical orthology framework with improved functional annotations for eukaryotic, prokaryotic and viral sequences. Nucleic Acids Res 44:D286-D293. https://doi.org/10.1093/nar/gkv1248.
48. Gardner SN, Hall BG. 2013. When whole-genome alignments just won't work: kSNP v2 software for alignment-free SNP discovery and phylogenetics of hundreds of microbial genomes. PLoS One 8:e81760. https://doi.org/10.1371/journal.pone.0081760.
49. McArthur AG, Waglechner N, Nizam F, Yan A, Azad MA, Baylay AJ, Bhullar K, Canova MJ, De Pascale G, Ejim L, Kalan L, King AM, Koteva K, Morar M, Mulvey MR, O'Brien JS, Pawlowski AC, Piddock LJ, Spanogiannopoulos P, Sutherland AD, Tang I, Taylor PL, Thaker M, Wang W, Yan M, Yu T, Wright GD. 2013. The comprehensive antibiotic resistance database. Antimicrob Agents Chemother 57:3348-3357. https://doi.org/10.1128/AAC.00419-13.
50. Chen L, Yang J, Yu J, Yao Z, Sun L, Shen Y, Jin Q. 2005. VFDB: A reference database for bacterial virulence factors. Nucleic Acids Res 33: D325-D328.
51. Micallef LRP. 2013. eulerAPE: drawing area-proportional Euler and Venn diagrams using ellipses. University of Kent, Canterbury, United Kingdom. http://www.eulerdiagrams.org/eulerAPE/. Accessed April 2017.